Impotence News and Research

RSS

Erectile dysfunction, sometimes called "impotence," is the repeated inability to get or keep an erection firm enough for sexual intercourse. The word "impotence" may also be used to describe other problems that interfere with sexual intercourse and reproduction, such as lack of sexual desire and problems with ejaculation or orgasm. Using the term erectile dysfunction makes it clear that those other problems are not involved.

Researchers study effectiveness of intermittent therapy for prostate cancer treatment

Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.

4 Apr 2013

Focal laser ablation uses targeted heat to burn away cancerous cells in prostate

Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option.

6 Mar 2013

Periodontal disease may predispose men to impotence

Men in their thirties with chronic gum disease are at significantly increased risk for erectile dysfunction, suggests a study by Turkish researchers.

7 Jan 2013

ARCHITECT 2nd Generation Testosterone Assay from Abbott

Testosterone is an important androgen hormone in the health and well-being of men and women. Testosterone levels are associated with sexual development, libido, protection against osteoporosis, and cardiovascular health. In men, insufficient testosterone levels (hypogonadism) have been linked to obesity and low libido.

18 Dec 2012

Men with prostate cancer can benefit from active surveillance

With active surveillance many men with prostate cancer could dispense with radiation treatment and surgery, and thus avoid adverse effects such as incontinence and impotence. This is the outcome of a study of almost 1,000 men diagnosed with prostate cancer conducted at Sahlgrenska Academy, University of Gothenburg, Sweden.

3 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

New prostate cancer therapy triggers questions about cost, effectiveness and safety

Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.

29 Oct 2012

First Edition: October 29, 2012

Today's headlines include reports about how the presidential election's outcome could impact the insurance industry as well as the fate of people who are sick or uninsured.

29 Oct 2012

National Proactive Surveillance Network launches today

The National Proactive Surveillance Network, the world's first online medical database designed to help men track the progression of their prostate cancer while avoiding complications from overtreatment, launches today.

25 Oct 2012

Abbott receives CE Marking for ARCHITECT testosterone assay

Abbott announced today CE Marking (Conformite Europeenne) for a testosterone assay with improved sensitivity and clinical utility.

28 Aug 2012

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI).

4 Jun 2012

Doctors disagree on new prostate cancer screening guidelines

One doctor suggests the problem is the rush to treatment, not the screening; another suggests that a failure to screen men could be more costly in the long run.

25 May 2012

PSA test benefits are questionable, yet physicians struggle to stop them

Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physicians, according to results of a survey by Johns Hopkins investigators.

24 May 2012

Federal task force recommends dropping routine prostate cancer test

The U.S. Preventive Services Task Force finds scant evidence that the PSA blood test saves lives and instead says unneeded treatment leads to serious problems, including impotence and incontinence.

23 May 2012

TJU researchers to investigate Cu-64 imaging agent for prostate cancer

Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.

17 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012